Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine plus prednisone vs prednisone as first-line therapy in primary immune thrombocytopenia
ChiCTR2300068387Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Kunming Medical University
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydroxychloroquine and prednisone in immune thrombocytopenia (ITP) (2 arms), sponsored by Second Affiliated Hospital of Kunming Medical University. Primary endpoint: Sustained response rate at 6 months. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
hydroxychloroquineprednisone
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2300068387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068387.